0
Editorials |

Treating Pulmonary Vascular Disease in the Developing World: The Single Step

Kamal K. Mubarak, MD, FCCP; Julio Sandoval, MD
Author and Funding Information

From the Division of Pulmonary, Critical Care, and Sleep Medicine (Dr Mubarak), University of Florida, and Cardiopulmonary Department (Dr Sandoval), National Institute of Cardiology of Mexico.

Correspondence to: Kamal K. Mubarak, MD, FCCP, 1600 SW Archer Rd, M452, Gainesville, FL 32610; e-mail: mubarak@ufl.edu


Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Mubarak has received grant funding from Actelion Pharmaceuticals, Gilead, Fibrogen, the National Institutes of Health, Novartis, and Pfizer. Dr Sandoval received grant funding from 2008 to 2010 from Actelion Pharmaceuticals, Bayer Schering, and PharmaBiotoscana SA, and his institution has received pharmaceutic company grant monies from 2007 to date from United Therapeutics (oral treprostinil in pulmonary arterial hypertension); Pfizer, Inc (sildenafil in children with pulmonary arterial hypertension), and Actelion Pharmaceuticals (macitentan in pulmonary arterial hypertension).

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestpubs.org/site/misc/reprints.xhtml).


© 2010 American College of Chest Physicians


Chest. 2010;137(6):1260-1262. doi:10.1378/chest.10-0476
Text Size: A A A
Published online

Extract

The Western world has taken huge strides in the treatment of pulmonary vascular disease (PVD). It began with clinical and then pathologic descriptions of pulmonary arterial hypertension (PAH), a subset of PVD. Subsequent mechanistic studies of vasoconstriction and hypertrophy, proliferation and clonality, and ventricular remodeling and contractility expanded our understanding of the disease. Genetic studies identified receptors, ligands, and pathways that cause heritable variants of the disease. Development of a clinicopathologic classification of pulmonary hypertension allowed for the categorization of the spectrum of PVD into well-defined groups based on pathophysiology. Close collaboration between clinical and basic scientists facilitated the identification of drug targets in PAH.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543